Acelyrin (SLRN) Adopts Limited-Duration Stockholder Rights Plan

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”).

The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.

Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close of business on March 24, 2025. The rights will initially trade with ACELYRIN’s common stock and will become exercisable only if any person acquires 10% or more of the Company’s outstanding common stock (20% in the case of a person who reports their beneficial ownership on Schedule 13G) (the “Triggering Percentage”). In that case, each holder of a right (other than the acquiring person, whose rights will become void and will not be exercisable) will be entitled to purchase, at the exercise price, additional shares of common stock having a then-current market value of twice such exercise price. Under the Rights Plan, any person who currently owns more than the applicable Triggering Percentage may continue to own its shares of common stock but may not acquire any additional shares without triggering the Rights Plan. In addition, the Rights Plan has customary flip-over and exchange features.

The Rights Plan is effective immediately and will expire on March 12, 2026.

ACELYRIN stockholders do not need to take any further action at this time.

Additional information regarding the Rights Plan will be contained in a Form 8-K to be filed by ACELYRIN with the U.S. Securities and Exchange Commission.

Guggenheim Securities, LLC is serving as financial advisor to ACELYRIN and Fenwick & West LLP and Paul Hastings LLP are serving as its legal counsel.

You May Also Be Interested In

• VivoPower shifts focus to AI data centers, revises unit spinoff plans
• Kite Realty closes $345M exchangeable senior notes offering
• Seer receives buyout proposal from its own CEO at $2.45 per share